#United States #New York #ImmunityBio #IBRX #Anktiva

Overview of the Lawsuit Against ImmunityBio

On April 30, 2026, SueWallSt announced a class action lawsuit targeting ImmunityBio, Inc. (NASDAQ: IBRX), initiated on behalf of shareholders who bought the company’s securities between January 19, 2026, and March 24, 2026. This lawsuit arises in the wake of significant stock value decline—around 21%—after an FDA warning letter disclosed misleading promotional claims regarding ImmunityBio's flagship drug, ANKTIVA. Under legal counsel Joseph E. Levi, shareholders allege that the company’s chairman misrepresented the drug's capabilities, leading investors to suffer substantial financial setbacks.

Background on ANKTIVA

ANKTIVA, which received FDA approval for treating a specific type of bladder cancer—namely BCG-unresponsive, high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ—claims to have achieved a complete response rate of 62% based on a limited trial involving 77 patients. However, it’s crucial to note that bladder cancer only accounts for about 4.2% of estimated new cancer cases, raising concerns about the validity of the promotional claims surrounding this drug.

Allegations of Misrepresentation

Key allegations within the lawsuit highlight that during the relevant class period, promotional communications significantly overstated the efficacy of ANKTIVA. Notable misrepresentations included:

• - Claims suggesting that ANKTIVA was capable of treating all cancers despite its approval being limited to a narrow subset of bladder cancer;
• - Presenting ANKTIVA as a cancer vaccine, neglecting to mention that it functions as an IL-15 receptor agonist with no vaccine action;
• - Suggesting that the drug could prevent cancer in patients exposed to radiation, a statement devoid of any supporting evidence; and
• - Promotional materials implied that ANKTIVA was suitable for subcutaneous injection, while its labeling stipulates intravesical use only.

Additionally, the FDA’s Office of Prescription Drug Promotion issued a warning letter emphasizing that both a television advertisement and a podcast featuring ImmunityBio's Executive Chairman violated regulations, stating that misleading representations posed significant public health concerns due to their impact on understanding the drug's benefits.

Impact on Stock and Shareholders

The stock price for IBRX fell by $1.98 per share following the FDA's warning letter, underscoring the significant backlash and loss for shareholders who may have been misled. The resultant decline raises critical inquiries regarding the responsibilities of companies to disclose accurate clinical trial data, particularly in the fluid and fast-paced biotech industry where promotional claims can heavily influence stock prices.

Participation in the Class Action

Shareholders who invested in IBRX securities during the stated period and experienced financial losses are encouraged to join the lawsuit. Joseph E. Levi, representing the plaintiffs, emphasizes that investors suffering harm due to reliance on the misrepresentation of information may be entitled to recover losses. Prospective participants must compile relevant brokerage records detailing their purchase dates, quantities of shares, and purchase prices to substantiate their claims.

Conclusion

This lawsuit could set a precedent in terms of accountability for biotechnology companies, stressing the importance of truthfulness in communications about drug efficacy. Investors affected should act promptly, gathering relevant information and engaging legal resources to ensure their rights to compensation are safeguarded.